ArticleBMC microbiology2025
Virulence factors, molecular characteristics, and resistance mechanisms of carbapenem-resistant Pseudomonas aeruginosa isolated from pediatric patients in Shanghai, China.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- Genetic Determinants Linked to MDR/XDR inPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe investigation into virulence factors, clinical and molecular characteristics, and resistance mechanisms of carbapenem-resistant Pseudomonas aeruginosa (CRPA) in pediatric populations is currently inadequate. PURPOSE: This study aimed to investigate the virulence factors, clinical and molecular characteristics, and resistance mechanisms of 135 CRPA isolates in Shanghai, China.
methodsAnalysis of virulence-associated genes and multilocus sequence typing (MLST) provided epidemiological and molecular insights into the isolates. Resistance mechanisms were identified via PCR, sequencing, and qRT-PCR.
resultsThe predominant resistance mechanism to carbapenems was the decreased production of outer membrane porin OprD (75.6%), accompanied by mutational inactivation of the oprD (87.4%). However, elevated production of AmpC (7.4%) and mexB overexpression (5.2%) were uncommon. Thirty-five sequence types (STs) were identified, with clonal complex 244 (CC244;59.3%) representing the majority of infections. Sixteen virulence factor genes were detected, with a significant portion of isolates (40.7%) concurrently possessing Toxin A (toxA), Elastase B (lasB), Exoenzyme S (exoS), staphylolysin (lasA), and Pilin (pilA). Almost all CC244 isolates carried toxA (100%), exoS (100%), pilA (100%), lasB (98.6%), and lasA (82.5%) while all ST2100, ST274, ST1129, ST446, and ST2069 isolates contained exoY. CC244 + isolates exhibited significantly increased antibiotic resistance, and the isolates from diseased or discharged patients showed comparatively higher resistance than others, except against gentamicin. Most patients (71.9%) received combination therapy, with 65.2% achieving clinical cure or improvement.
conclusionThis study predominantly identified OprD-mediated carbapenem resistance in pediatric patients. The CRPA isolates were characterized by a variety of STs and a widespread distribution of virulence-associated genes. CC244 demonstrated significantly higher resistance, with potential outbreaks occurring in 2018 and 2019. These findings could aid in managing nosocomial CRPA infections and enhancing clinical practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.